Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells

Wang,Linhui; Huang,Ting; Chen,Wei; Gao,Xiaofeng; Zhou,Tie; Wu,Zhenjie; Sun,Yinghao

doi:10.3892/or.2012.2028

Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells

Authors:
- Linhui Wang
- Ting Huang
- Wei Chen
- Xiaofeng Gao
- Tie Zhou
- Zhenjie Wu
- Yinghao Sun
View Affiliations

Affiliations: Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: September 12, 2012 https://doi.org/10.3892/or.2012.2028
Pages: 2043-2048

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is the third most common genitourinary malignancy, accounting for 3% of cancer in adults. The mortality and morbidity of RCC is strongly associated with its high propensity to metastasize to specific organs. This may be attributed to the fact that the CXCR4 G protein-coupled receptor (GPCR) on RCC cells mediates chemoattraction toward stromal-derived factor 1 (SDF-1) secreted by target organs. RNA interference (RNAi), which has been proven to be a powerful tool for suppressing gene expression, may lead to novel strategies for treating RCC. Our previous experiments confirmed that RCC A-498 cells overexpressing CXCR4 are associated with increased invasiveness. In this study, we constructed recombinant CXCR4-RNAi plasmids and transfected them into A-498 cells in vitro. Reverse transcription polymerase chain reaction (RT-PCR) and western blotting revealed that CXCR4 was downregulated in transfected cells compared with control cells. Our results from MTT and transwell migration assays indicated that specific downregulation of CXCR4 inhibited cell growth, invasiveness and migration. Flow cytometric analysis indicated that silencing of CXCR4 in A-498 cells by RNA interference induced cell apoptosis in RCC in vitro. Thus, siRNA targeting of CXCR4 can effectively inhibit the growth and metastasis of RCC cells and may be a promising innovative anticancer therapy.

View Figures

View References

1	Godley P and Kim SW: Renal cell carcinoma. Curr Opin Oncol. 14:280–285. 2002. View Article : Google Scholar
2	Fishman M and Seigne J: Immunotherapy of metastatic renal cell cancer. Cancer Control. 9:293–304. 2002.PubMed/NCBI
3	Vicari AP and Caux C: Chemokines in cancer. Cytokine Growth Factor Rev. 13:143–154. 2002. View Article : Google Scholar
4	Navarini-Meury AA and Conrad CC: Melanoma and innate immunity-active inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines. Semin Cancer Biol. 19:84–91. 2009.
5	Skommer J, Wlodkowic D and Pelkonen J: CXCR4 expression during tumour cell death. Leuk Res. 31:1155–1156. 2007. View Article : Google Scholar : PubMed/NCBI
6	Burger JA and Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 107:1761–1767. 2006. View Article : Google Scholar : PubMed/NCBI
7	Broxmeyer HE, Orschell CM and Clapp DW: Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 201:1293–1305. 2005. View Article : Google Scholar : PubMed/NCBI
8	Labrosse B, Brelot A and Heveker N: Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol. 72:6381–6388. 1998.PubMed/NCBI
9	Hendrix CW, Collier AC, Lederman MM, et al: Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 37:1253–1262. 2004. View Article : Google Scholar : PubMed/NCBI
10	Paul S, Mancuso P, Rabascio C, et al: In Vitro and Preclinical Activity of the Novel AMD3100 CXCR4 Antagonist in Lymphoma Models. In: American Society of Hematology Annual Meeting; 2002; Philadelphia, PA, USA. Blood. 2002
11	Duxbury MS and Whang EE: RNA interference: a practical approach. J Surg Res. 117:339–344. 2004. View Article : Google Scholar : PubMed/NCBI
12	Wang L, Wang Z, Yang B, et al: CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma. Oncol Rep. 22:1333–1339. 2009.PubMed/NCBI
13	Zlotnik A and Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity. 12:121–127. 2000. View Article : Google Scholar : PubMed/NCBI
14	Zlotnik A: Chemokines and cancer. Int J Cancer. 119:2026–2029. 2006. View Article : Google Scholar : PubMed/NCBI
15	Kim J, Takeuchi H, Lam ST, et al: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 23:2744–2753. 2005. View Article : Google Scholar : PubMed/NCBI
16	Hiller DJ, Li BD and Chu QD: CXCR4 as a predictive marker for locally advanced breast cancer post-neoadjuvant therapy. J Surg Res. 166:14–18. 2011. View Article : Google Scholar : PubMed/NCBI
17	Xie L, Wei J, Qian X, et al: CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer. Anticancer Res. 30:2209–2216. 2010.PubMed/NCBI
18	Spoo AC, Lubbert M and Wierda WG: CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 109:786–791. 2007. View Article : Google Scholar : PubMed/NCBI
19	Laverdiere C, Hoang BH and Yang R: Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 11:2561–2567. 2005. View Article : Google Scholar : PubMed/NCBI
20	Sun YX, Wang J, Shelburne CE, et al: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 89:462–473. 2003. View Article : Google Scholar : PubMed/NCBI
21	Zagzag D, Krishnamachary B, Yee H, et al: Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65:6178–6188. 2005. View Article : Google Scholar : PubMed/NCBI
22	Thomas CW, Claudine G, Stefan B, et al: Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease. J Oncol. 2008:1–6. 2008. View Article : Google Scholar : PubMed/NCBI
23	Wang LH, Liu Q, Xu B, et al: Identification of nuclear localization sequence of CXCR4 in renal cell carcinoma by constructing expression plasmids of different deletants. Plasmid. 63:68–72. 2010. View Article : Google Scholar : PubMed/NCBI
24	Lin SY, Makino K, Xia W, et al: Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 3:802–808. 2001. View Article : Google Scholar : PubMed/NCBI
25	Sherr CJ: Cancer cell cycles. Science. 274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
26	Khan MZ, Shimizu S, Patel JP, et al: Regulation of neuronal P53 activity by CXCR 4. Mol Cell Neurosci. 30:58–66. 2005. View Article : Google Scholar : PubMed/NCBI
27	Gerlach LO, Skerlj RT, Bridger GJ, et al: Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem. 276:14153–14160. 2001.PubMed/NCBI
28	Dewan MZ, Ahmed S, Iwasaki Y, et al: Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 60:273–276. 2006. View Article : Google Scholar : PubMed/NCBI
29	Burger M, Glodek A, Hartmann T, et al: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 22:8093–8101. 2003. View Article : Google Scholar : PubMed/NCBI
30	Hartmann TN, Burger JA, Glodek A, et al: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 24:4462–4471. 2005. View Article : Google Scholar : PubMed/NCBI
31	Chao DT and Korsmeyer SJ: Bcl-2 family: regulators of cell death. Annu Rev Immunol. 16:395–419. 1998. View Article : Google Scholar
32	Carmen HL, Jaris V, Laura Hi, et al: CXCL12/CXCR4 signaling promotes human thymic dendritic cell survival regulating the Bcl-2/Bax ratio. Immunol Lett. 120:72–78. 2008. View Article : Google Scholar : PubMed/NCBI
33	Zheng H, Dai T, Zhou B, et al: SDF-1alpha/CXCR4 decreases endothelial progenitor cells apoptosis under serum deprivation by PI3K/Akt/eNOS pathway. Atherosclerosis. 201:36–42. 2008. View Article : Google Scholar : PubMed/NCBI
34	Gao F, Gao E, Yue TL, et al: Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 105:1497–1502. 2002. View Article : Google Scholar
35	Yin G, Li LY, Qu M, Luo HB, Wang JZ and Zhou XW: Upregulation of AKT attenuates amyloid-β-induced cell apoptosis. J Alzheimers Dis. 25:337–345. 2011.
36	New DC, Wu K, Kwok AW, et al: G protein-coupled receptor-induced Akt activity in cellular proliferation and apoptosis. FEBS J. 274:6025–6036. 2007. View Article : Google Scholar : PubMed/NCBI
37	Ljungberg B, Cowan NC, Hanbury DC, et al: EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 58:401–402. 2010. View Article : Google Scholar : PubMed/NCBI